Skip to main content
. 2015 Apr 14;10(4):e0123866. doi: 10.1371/journal.pone.0123866

Fig 4. Comparison of the incidence of PN in patients treated with IV and SC bortezomib in the IFM trial and CMG analysis.

Fig 4